Evaluation of a histocompatibility antigen related to hepatitis B virus in patients with hepatocellular carcinoma in the western Brazilian Amazon

Chalub, Sidney Raimundo Silva; Silva, R.M. da; Silva, A.P.S. da; Aquino, Priscila Ferreira de; Sadahiro, Aya; Kalil, A.

doi:10.4238/2013.april.25.5

Cited by 2 publications

(2 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, we think that the strengths of the study were that two HLA alleles in our study (HLA-A*11 and HLA-C*01) were associated with the mortality after controlling for SOFA or APACHE-II. In addition, the three HLA alleles associated with the mortality in our study (HLA-A*11, HLA-DQB1*04 and HLA-C*01), previously were associated with poor evolution in other infectious diseases (HLA-A*11 22,23 and HLA-DQB1*04 29,30 ) or with the risk of other infectious diseases (HLA-C*01 24 ).…”

Section: Discussionsupporting

confidence: 57%

See 1 more Smart Citation

HLA genetic polymorphisms and prognosis of patients with COVID-19

et al. 2021

View full text Add to dashboard Cite

Objetivo: Diferentes polimorfismos genéticos de los antígenos leucocitarios humanos (HLA) están asociados con el riesgo y el pronóstico de enfermedades autoinmunes e infecciosas. Los objetivos de estudio fueron determinar si existe una asociación entre polimorfismos genéticos de HLA y la susceptibilidad y mortalidad de pacientes con la enfermedad del coronavirus 2019 (COVID-19). Diseño: Estudio observacional y prospectivo Ámbito: Ocho Unidades de Cuidados Intensivos (UCI) de 6 hospitales de las islas canarias (España). Pacientes: Pacientes COVID-19 ingresados en UCI y sujetos sanos. Intervenciones: Se determinaron los polimorfismos genéticos de HLA Variable de interés principal: Mortalidad a los 30 días Resultados: Se incluyeron 3886 sujetos sanos y 72 pacientes COVID-19 (10 fallecidos y 62 supervivientes a 30 días). Encontramos una tendencia a una mayor frecuencia de los alelos HLA-A*32 (p=0.004) en sujetos sanos que en pacientes COVID-19, y de los alelos HLA-B*39 (p=0.02) y HLA-C*16 (p=0.02) en pacientes COVID-19 que en sujetos sanos; sin embargo, no fueron significativos al corregir por comparaciones múltiples. En la regresión logística encontramos que la presencia de ciertos alelos estuvo asociada con mayor mortalidad, como el alelo HLA-A*11 controlando por SOFA (OR=7.693; 95% CI=1.063-55.650; p=0.04) o APACHE-II (OR=11.858; 95% CI=1.524-92.273; p=0.02), el alelo HLA-C*01 controlando por SOFA (OR=11.182; 95% CI=1.053-118.700; p=0.04) o APACHE-II (OR=17.604; 95% CI=1.629-190.211; p=0.02), y el alelo HLA-DQB1*04 controlando por SOFA (OR=9.963; 95% CI=1.235-80.358; p=0.03). Conclusiones: Los nuevos hallazgos de nuestro preliminar estudio de pequeño tamaño muestral fueron que determinados polimorfismos genéticos de HLA podrían estar asociados con la mortalidad de pacientes COVID-19; sin embargo, estudios de mayor tamaño muestral son necesarios para concluirlo definitivamente.

show abstract

Section: Discussionsupporting

confidence: 57%

“…23 Besides, the presence of HLA-DQB1*04 has been associated with poor evolution of patients with HBV. 29,30 However, to the best of our knowledge, no study has evaluated this aspect in patients with COVID-19.…”

Section: Discussionmentioning

confidence: 99%

HLA genetic polymorphisms and prognosis of patients with COVID-19

et al. 2021

View full text Add to dashboard Cite

show abstract

HLA genetic polymorphisms and prognosis of patients with COVID-19

Lorente

Franco

Barrios

et al. 2021

Medicina Intensiva (English Edition)

View full text Add to dashboard Cite

Objective Different genetic polymorphisms of human leukocyte antigen (HLA) have been associated with the risk and prognosis of autoimmune and infectious diseases. The objectives of this study were to determine whether there is an association between HLA genetic polymorphisms and the susceptibility to and mortality of coronavirus disease 2019 (COVID-19) patients. Design Observational and prospective study. Setting Eight Intensive Care Units (ICU) from 6 hospitals of Canary Islands (Spain). Patients COVID-19 patients admitted in ICU and healthy subjects. Interventions Determination of HLA genetic polymorphisms. Main variable of interest Mortality at 30 days. Results A total of 3886 healthy controls and 72 COVID-19 patients (10 non-survivors and 62 survivor patients at 30 days) were included. We found a trend to a higher rate of the alleles HLA-A*32 ( p = 0.004) in healthy controls than in COVID-19 patients, and of the alleles HLA-B*39 ( p = 0.02) and HLA-C*16 ( p = 0.02) in COVID-19 patients than in healthy controls; however, all these p-values were not significant after correction for multiple comparisons. Logistic regression analysis showed that the presence of certain alleles was associated with higher mortality, such as the allele HLA-A*11 after controlling for SOFA (OR = 7.693; 95% CI = 1.063–55.650; p = 0.04) or APACHE-II (OR = 11.858; 95% CI = 1.524–92.273; p = 0.02), the allele HLA-C*01 after controlling for SOFA (OR = 11.182; 95% CI = 1.053–118.700; p = 0.04) or APACHE-II (OR = 17.604; 95% CI = 1.629–190.211; p = 0.02), and the allele HLA-DQB1*04 after controlling for SOFA (OR = 9.963; 95% CI = 1.235–80.358; p = 0.03). Conclusions The new finding from our preliminary study of small sample size was that HLA genetic polymorphisms could be associated with COVID-19 mortality; however, studies with a larger sample size before definitive conclusions can be drawn.

show abstract

Evaluation of a histocompatibility antigen related to hepatitis B virus in patients with hepatocellular carcinoma in the western Brazilian Amazon

Cited by 2 publications

References 16 publications

HLA genetic polymorphisms and prognosis of patients with COVID-19

HLA genetic polymorphisms and prognosis of patients with COVID-19

HLA genetic polymorphisms and prognosis of patients with COVID-19

Contact Info

Product

Resources

About